MetaVia Inc. reported a Q3 2026 net loss of $4.6 million as it advances its clinical pipeline for liver-related cardiometabolic diseases. The company highlighted positive 16-week interim data for DA-1726, showing a 68.1% placebo-adjusted reduction in liver fat, and confirmed plans to initiate a 48-week Phase 2 study in MetALD and ALD patients in the second half of 2027.
Bullish
🤖 65%
The Q3 2026 report recaps strong DA-1726 interim Phase 1 data: 68.1% placebo-adjusted liver fat reduction, 13.5% placebo-adjusted weight loss and a statistically significant 1.47 mg/dL uric acid drop, supporting a 48-week Phase 2 in up to 150 MetALD/ALD patients targeted for H2 2027. For a clinical-stage biotech, de-risked pipeline progress is the main value driver. Counterweights are rising costs (R&D up to ~$2.6 million from ~$1.9 million, G&A up to ~$2.1 million from ~$1.6 million) and headline data already having been announced earlier in November.
Catalysts
- ▲ Full Phase 1 Parts 3A/3B data expected in Q1 2027
- ▲ Phase 2 study in MetALD/ALD (up to 150 subjects, 48 weeks) targeted for H2 2027
Risk Factors
- ▼ R&D expenses rose to approximately $2.6 million from approximately $1.9 million year-over-year, and G&A to approximately $2.1 million from approximately $1.6 million, increasing cash burn
- ▼ The 68.1% liver fat reduction interim data were already presented earlier in November 2026, so much of the news may be priced in